SCHEMBL2575320

SCHEMBL2575320

Clc1nc(-c2ccc(Br)cc2)cc2nccn12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
GAA P10253 4/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
AHR P35869 3/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.39
MGAM O43451 3/20 0.38
SI P14410 3/20 0.38
MGAM2 Q2M2H8 3/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084455 0.80 IDO1 (0.42) IDO1
SCHEMBL6495343 0.77 SYK (0.55) KDM4EALDH1A1NPC1RAB9AMAPT
SCHEMBL2553234 0.76 XDH (0.46) KDM4EALDH1A1NPC1RAB9AGAA
SCHEMBL2574011 0.75 PDE3A (0.40) IDO1KDM4EALDH1A1NPC1RAB9A
SCHEMBL2553734 0.74 FGFR3 (0.45)
SCHEMBL2576052 0.74 DRD4 (0.42)
SCHEMBL3599775 0.73 EGLN2 (0.51) KDM4EALDH1A1NPC1RAB9AMAPT
SCHEMBL2571757 0.72 PDE10A (0.33)
SCHEMBL28873688 0.69 ADORA2A (0.37) KDM4EALDH1A1NPC1MEN1KMT2A
SCHEMBL30318567 0.67 IDO1 (0.31) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558468-B1 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC (US) 2015-04-01 EP disclosed
US-8962596-B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases ARRAY BIOPHARMA INC. (US) 2015-02-24 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
EP-2558468-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES Array Biopharma, Inc. (US) 2013-02-20 EP disclosed
WO-2011130146-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES JAK1, JAK3, JAK2 IDO1 344/4885KDM4E 1383/4885ALDH1A1 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.